RVAC Medicines Presented at the 2nd mRNA-Based Therapeutics Summit Europe Event 2023

Dr. Stefano Gulla, VP of Therapeutics at RVAC Medicines, presented progress on our mRNA-encoded antibody platform at the 2nd mRNA-Based Therapeutics Summit Europe Event 2023. His presentation, titled “Defining Early Biomarkers of Pharmacology for Intravenously Administered mRNA-Encoded Therapeutic Antibodies in Non-Human Primates,”  highlighted data from our discovery and development of a mRNA therapeutic pipeline. RVAC is actively working on multiple preclinical programs supported by the mRNA-encoded antibody platform with potential applications in oncology, infectious diseases, and autoimmune diseases. The presentation took place on January 26, 2023, in Berlin, Germany. 

For more information, please visit  https://mrnabased-therapeutics-europe.com/.